Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Conba Pharmaceutical CoSHSE:600572 +2.36%73 Net Current Asset Value is ¥0.76 as of Mar. 2026, which is 100% below its 10-year median of 8.96. GuruFocus rates SHSE:600572 with a GF Score™ of 73/100 and a GF Value™ of ¥5.56 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 607 Drug Manufacturers companies, Zhejiang Conba Pharmaceutical Co ranks better than 51.24% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for Zhejiang Conba Pharmaceutical Co's Net Current Asset Value or its related term are showing as below:
SHSE:600572'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.54 Med: 8.96 Max: 665
Current: 5.71
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Zhejiang Conba Pharmaceutical Co was 665.00. The lowest was 5.54. And the median was 8.96.
SHSE:600572's Price-to-Net-Current-Asset-Value is ranked better than 51.24% of 607
companies
in the Drug Manufacturers industry
Industry Median: 5.84
vs SHSE:600572: 5.71
Zhejiang Conba Pharmaceutical Co (SHSE:600572) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Zhejiang Conba Pharmaceutical Co Net Current Asset Value Related Terms
Zhejiang Conba Pharmaceutical Co Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co Net Current Asset Value Chart
SHSE:600572 vs ZTS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Conba Pharmaceutical Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Conba Pharmaceutical Co Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Conba Pharmaceutical Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Zhejiang Conba Pharmaceutical Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ¥0.76 mean?
Zhejiang Conba Pharmaceutical Co (SHSE:600572) has a Net Current Asset Value of ¥0.76 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. This is 92% below median its historical median of 8.96. Over the past decade, Zhejiang Conba Pharmaceutical Co's Net Current Asset Value has ranged from 5.54 to 665.00. According to the industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #296 out of 607 companies in the Drug Manufacturers industry, placing it in the top 48.8%.
Is Zhejiang Conba Pharmaceutical Co's Net Current Asset Value too high?
Zhejiang Conba Pharmaceutical Co's current Net Current Asset Value of ¥0.76 is 92% below median its 10-year median of 8.96. Over the past 10 years, this metric has ranged from a low of 5.54 to a high of 665.00. Based on the distribution chart, Zhejiang Conba Pharmaceutical Co ranks #296 out of 607 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zhejiang Conba Pharmaceutical Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Conba Pharmaceutical Co's Net Current Asset Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #296 out of 607 companies for Net Current Asset Value. This puts Zhejiang Conba Pharmaceutical Co in the upper half of its industry. The industry median Net Current Asset Value is 5.84. Historically, Zhejiang Conba Pharmaceutical Co's own Net Current Asset Value has ranged from 5.54 to 665.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.84, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Conba Pharmaceutical Co's current Net Current Asset Value is ¥0.76, which is 92% below median its own 10-year median of 8.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Conba Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co (SHSE:600572) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.56, compared to a current price of ¥4.34 — trading 21.9% below its estimated fair value. The current Net Current Asset Value is ¥0.76, which is 92% below median its 10-year median of 8.96. Zhejiang Conba Pharmaceutical Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Zhejiang Conba Pharmaceutical Co (SHSE:600572), the current Net Current Asset Value is ¥0.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥4.34 is trading 21.9% below its estimated GF Value™ of ¥5.56.
GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600572:
Net Current Asset Value: ¥0.76 (92% below median its 10-year median of 8.96)
GF Value™: ¥5.56 vs. price of ¥4.34 (21.9% below fair value)
No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
73GF Score
Get the complete analysis for SHSE:600572
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600572 has been successfully added to your 
